Norio Asou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Norio Asou has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
H Mitsuya
Department of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
4 shared publicationsN Matsuno
Department of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
4 shared publicationsT Kawakita
Department of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
4 shared publicationsT Nanri
Department of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
4 shared publicationsH Suzushima
Department of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
2 shared publicationsHitoshi Suzushima
From Second Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan; and the Departments of Viral Oncology and of Genetics and Molecular Biology, Institute for Virus Research, Kyoto University, Kyoto, Japan
2 shared publications
Latest Publications
- 1 January 2007
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 46 (2) , 91-94
2. All-trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
- 1 January 2007
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 46 (2) , 91-94
2. All-trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
- 28 July 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (9) , 1673-1675
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation
- 28 July 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (9) , 1673-1675
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation
- 19 May 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (8) , 1361-1366
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
AML1-MTG8 generated by t(8;21) contributes to leukemic transformation, but additional events are required for full leukemogenesis. We examined whether mutations in the receptor tyrosine kinase (RTK) pathway could be the genetic events that cause acute myeloblastic leukemia (AML) harboring t(8;21). Mutations in the second tyrosine kinase domain, juxtamembrane (JM) domain and exon 8 of the C-KIT gene were observed in 10, one and three of 37 AML patients with t(8;21), respectively. Three patients showed an internal tandem duplication in the JM domain of the FLT3 gene. One patient had a mutation in the K-Ras gene at codon 12. As the occurrence of these mutations was mutually exclusive, a total of 18 (49%) patients showed mutations in the RTK pathway. These results suggest that activating mutations in the RTK pathway play a role in part as an additional event leading to the development of t(8;21) AML. The 6-year cumulative incidence of relapse in patients with RTK pathway mutations was 79.8%, compared with 13.5% in patients lacking such mutations (P=0.0029). Furthermore, the 6-year relapse-free survival in patients with mutations was 18% compared to 60% in those without mutations (P=0.0340), indicating that RTK mutations are associated with the clinical outcome in t(8;21) AML.
- 19 May 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (8) , 1361-1366
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
AML1-MTG8 generated by t(8;21) contributes to leukemic transformation, but additional events are required for full leukemogenesis. We examined whether mutations in the receptor tyrosine kinase (RTK) pathway could be the genetic events that cause acute myeloblastic leukemia (AML) harboring t(8;21). Mutations in the second tyrosine kinase domain, juxtamembrane (JM) domain and exon 8 of the C-KIT gene were observed in 10, one and three of 37 AML patients with t(8;21), respectively. Three patients showed an internal tandem duplication in the JM domain of the FLT3 gene. One patient had a mutation in the K-Ras gene at codon 12. As the occurrence of these mutations was mutually exclusive, a total of 18 (49%) patients showed mutations in the RTK pathway. These results suggest that activating mutations in the RTK pathway play a role in part as an additional event leading to the development of t(8;21) AML. The 6-year cumulative incidence of relapse in patients with RTK pathway mutations was 79.8%, compared with 13.5% in patients lacking such mutations (P=0.0029). Furthermore, the 6-year relapse-free survival in patients with mutations was 18% compared to 60% in those without mutations (P=0.0340), indicating that RTK mutations are associated with the clinical outcome in t(8;21) AML.
- 30 December 2004
- Published by Springer Nature in Leukemia
- Vol. 19 (3) , 480-481
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia
- 30 December 2004
- Published by Springer Nature in Leukemia
- Vol. 19 (3) , 480-481
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia
- 15 April 2004
- Published by Springer Nature in Leukemia
- Vol. 18 (6) , 1146-1148
Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics
- 15 April 2004
- Published by Springer Nature in Leukemia
- Vol. 18 (6) , 1146-1148
Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics
- 1 February 2003
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 45 (2) , 129-150
The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications
- 1 February 2003
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 45 (2) , 129-150
The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications
- Open Access
- 15 March 1999
- Published by American Society of Hematology in Blood
- Vol. 93 (6) , 1817-1824
Biallelic and Heterozygous Point Mutations in the Runt Domain of theAML1/PEBP2B Gene Associated With Myeloblastic Leukemias
The AML1 gene encoding the DNA-binding -subunit in the Runt domain family of heterodimeric transcription factors has been noted for its frequent involvement in chromosomal translocations associated with leukemia. Using reverse transcriptase-polymerase chain reaction (RT-PCR) combined with nonisotopic RNase cleavage assay (NIRCA), we found point mutations of the AML1 gene in 8 of 160 leukemia patients: silent mutations, heterozygous missense mutations, and biallelic nonsense or frameshift mutations in 2, 4, and 2 cases, respectively. The mutations were all clustered within the Runt domain. Missense mutations identified in 3 patients showed neither DNA binding nor transactivation, although being active in heterodimerization. These defective missense mutants may be relevant to the predisposition or progression of leukemia. On the other hand, the biallelic nonsense mutants encoding truncated AML1 proteins lost almost all functions examined and may play a role in leukemogenesis leading to acute myeloblastic leukemia.
- 15 March 1999
- Published by American Society of Hematology in Blood
- Vol. 93 (6) , 1817-1824
Open AccessBiallelic and Heterozygous Point Mutations in the Runt Domain of theAML1/PEBP2B Gene Associated With Myeloblastic Leukemias
The AML1 gene encoding the DNA-binding -subunit in the Runt domain family of heterodimeric transcription factors has been noted for its frequent involvement in chromosomal translocations associated with leukemia. Using reverse transcriptase-polymerase chain reaction (RT-PCR) combined with nonisotopic RNase cleavage assay (NIRCA), we found point mutations of the AML1 gene in 8 of 160 leukemia patients: silent mutations, heterozygous missense mutations, and biallelic nonsense or frameshift mutations in 2, 4, and 2 cases, respectively. The mutations were all clustered within the Runt domain. Missense mutations identified in 3 patients showed neither DNA binding nor transactivation, although being active in heterodimerization. These defective missense mutants may be relevant to the predisposition or progression of leukemia. On the other hand, the biallelic nonsense mutants encoding truncated AML1 proteins lost almost all functions examined and may play a role in leukemogenesis leading to acute myeloblastic leukemia.
- 1 January 1998
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 16 (1) , 78-85
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
PURPOSE: We conducted a multicenter study of differentiation therapy with all-trans retinoic acid (ATRA) followed by intensive chemotherapy in patients with newly diagnosed acute promyelocytic leukemia (APL) and analyzed the prognostic factors for predicting complete remission (CR), event-free survival (EFS), and disease-free survival (DFS). PATIENTS AND METHODS: All patients received ATRA until CR. If patients had an initial leukocyte count greater than 3.0 x 10(9)/L, they received daunorubicin (DNR) and behenoyl cytarabine (BHAC). During therapy, if patients showed blast and promyelocyte counts greater than 1.0 x 10(9)/L, they received additional DNR and BHAC. After achieving CR, patients received three courses of consolidation and six courses of maintenance/intensification chemotherapy. RESULTS: Of 198 registered, 196 were assessable (age range, 15 to 86 years; median, 46) and 173 (88%) achieved CR. Multivariate analysis showed that no or minor purpura at diagnosis (P = .0046) and age less than 30 years (P = .0076) were favorable factors for achievement of CR. Predicted 4-year overall survival and EFS rates were 74% and 54%, respectively, and the 4-year predicted DFS rate for 173 CR patients was 62%. Multivariate analysis showed that age less than 30 years (P = .0003) and initial leukocyte count less than 10 x 10(9)/L (P = .0296) were prognostic factors for longer EFS, and initial leukocyte count less than 10.0 x 10(9)/L was a sole significant prognostic factor for longer DFS (P = .0001). CONCLUSION: Our results show that age, hemorrhagic diathesis, and initial leukocyte count are prognostic factors for APL treated with ATRA followed by intensive chemotherapy.
- 1 January 1998
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 16 (1) , 78-85
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
PURPOSE: We conducted a multicenter study of differentiation therapy with all-trans retinoic acid (ATRA) followed by intensive chemotherapy in patients with newly diagnosed acute promyelocytic leukemia (APL) and analyzed the prognostic factors for predicting complete remission (CR), event-free survival (EFS), and disease-free survival (DFS). PATIENTS AND METHODS: All patients received ATRA until CR. If patients had an initial leukocyte count greater than 3.0 x 10(9)/L, they received daunorubicin (DNR) and behenoyl cytarabine (BHAC). During therapy, if patients showed blast and promyelocyte counts greater than 1.0 x 10(9)/L, they received additional DNR and BHAC. After achieving CR, patients received three courses of consolidation and six courses of maintenance/intensification chemotherapy. RESULTS: Of 198 registered, 196 were assessable (age range, 15 to 86 years; median, 46) and 173 (88%) achieved CR. Multivariate analysis showed that no or minor purpura at diagnosis (P = .0046) and age less than 30 years (P = .0076) were favorable factors for achievement of CR. Predicted 4-year overall survival and EFS rates were 74% and 54%, respectively, and the 4-year predicted DFS rate for 173 CR patients was 62%. Multivariate analysis showed that age less than 30 years (P = .0003) and initial leukocyte count less than 10 x 10(9)/L (P = .0296) were prognostic factors for longer EFS, and initial leukocyte count less than 10.0 x 10(9)/L was a sole significant prognostic factor for longer DFS (P = .0001). CONCLUSION: Our results show that age, hemorrhagic diathesis, and initial leukocyte count are prognostic factors for APL treated with ATRA followed by intensive chemotherapy.
- 1 January 1998
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 31 (1-2) , 81-91
Acute Myelomonoblastic Leukemia Carrying the PEBP2β/MYH11 Fusion Gene
As recurrent chromosome abnormalities in leukemia are highly associated with particular subtypes, the genetic events of specific chromosome alteration must be associated with leukemo-genesis and characteristics of the disease. The chromosomal breakpoints involved in inv(16) and t(16;16) have been shown to generate the fusion gene PEBP2β(CBFβ)/MYH11. The PEBP2β/MYH11 fusion transcripts in all 8 patients with M4Eo, 2 of 18 with M4, and one CML in the blastic phase were detected by using RT-PCR and Southern blotting. We demonstrated the marked expression of CD34 and c-KIT (CD 117) antigens in myelomonoblastic leukemia cells from all patients carrying this fusion gene, which was in contrast to the patients with M4 but without the fusion gene. These results indicate that immunophenotypic analysis is useful for detection of leukemia with the fusion gene, and that the PEBP2β/MYH11 fusion gene is involved in immature cells expressing CD34 and c-KIT antigens.
- 1 January 1998
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 31 (1-2) , 81-91
Acute Myelomonoblastic Leukemia Carrying the PEBP2β/MYH11 Fusion Gene
As recurrent chromosome abnormalities in leukemia are highly associated with particular subtypes, the genetic events of specific chromosome alteration must be associated with leukemo-genesis and characteristics of the disease. The chromosomal breakpoints involved in inv(16) and t(16;16) have been shown to generate the fusion gene PEBP2β(CBFβ)/MYH11. The PEBP2β/MYH11 fusion transcripts in all 8 patients with M4Eo, 2 of 18 with M4, and one CML in the blastic phase were detected by using RT-PCR and Southern blotting. We demonstrated the marked expression of CD34 and c-KIT (CD 117) antigens in myelomonoblastic leukemia cells from all patients carrying this fusion gene, which was in contrast to the patients with M4 but without the fusion gene. These results indicate that immunophenotypic analysis is useful for detection of leukemia with the fusion gene, and that the PEBP2β/MYH11 fusion gene is involved in immature cells expressing CD34 and c-KIT antigens.